How many stocks are there of Carmat?
The current number of stocks of Carmat is 24.79 M undefined.
Carmat Stocks 2025
Carmat Stocks
24.79 M
Ticker
ALCAR.PA
ISIN
FR0010907956
WKN
A1C017
In 2025, Carmat had 24.79 M outstanding stocks, a 0% change from the 24.79 M stocks in the previous year.
The Carmat Stocks history
| YEAR | NUMBER OF STOCKS (undefined EUR) |
|---|---|
| 2027e | 24.79 |
| 2026e | 24.79 |
| 2025e | 24.79 |
| 2024e | 24.79 |
| 2023 | 24.79 |
| 2022 | 22.68 |
| 2021 | 15.57 |
| 2020 | 9.27 |
| 2019 | 9.27 |
| 2018 | 9.27 |
| 2017 | 9.01 |
| 2016 | 6.03 |
| 2015 | 4.51 |
| 2014 | 4.38 |
| 2013 | 4.28 |
| 2012 | 4.14 |
| 2011 | 4.13 |
| 2010 | 2.88 |
| 2009 | 2.88 |
Carmat shares outstanding FR0010907956 · A1C017
The number of shares was Carmat in 2024 — This indicates how many shares 24.788 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Carmat earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Carmat's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Carmat’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Carmat's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2009 | 2.88 M Aktien |
| 2010 | 2.88 M Aktien |
| 2011 | 4.13 M Aktien |
| 2012 | 4.14 M Aktien |
| 2013 | 4.28 M Aktien |
| 2014 | 4.38 M Aktien |
| 2015 | 4.51 M Aktien |
| 2016 | 6.03 M Aktien |
| 2017 | 9.01 M Aktien |
| 2018 | 9.27 M Aktien |
| 2019 | 9.27 M Aktien |
| 2020 | 9.27 M Aktien |
| 2021 | 15.57 M Aktien |
| 2022 | 22.68 M Aktien |
| 2023 | 24.79 M Aktien |
| 2024e | 24.79 M Aktien |
| 2025e | 24.79 M Aktien |
| 2026e | 24.79 M Aktien |
| 2027e | 24.79 M Aktien |
Carmat Aktienanalyse
What does Carmat do?
Carmat SA is a French company that was founded in 2008 and is headquartered in Vélizy-Villacoublay, France. The company is involved in the development, manufacture, and sale of cardiovascular systems and artificial hearts. Carmat is a leader in developing technologies for the treatment of serious heart conditions and aims to provide highly innovative solutions for patients suffering from end-stage heart failure. The business model of Carmat is based on the development and commercialization of products that contribute to improving the quality of life for patients with serious heart conditions. The artificial hearts are made from biocompatible materials and can be implanted in human bodies. They can serve as a bridge to a heart transplant or even as a permanent solution for complete replacement of the natural heart. Carmat is divided into various divisions including research and development, production, sales, and marketing. The company's research and development department works on developing highly specialized technologies for the artificial hearts to enhance performance and reliability. The production department manufactures the artificial hearts and ensures a strictly controlled, sterile environment to ensure the highest quality of products. The sales and marketing team ensures that the artificial hearts are marketed and sold worldwide. Carmat currently offers the Carmat heart, which is considered a revolutionary product in the market. The heart is made from biocompatible materials and is produced through a strictly controlled process. It has been designed to maximize performance and reliability in an artificial heart solution. The artificial hearts are implanted in an elaborate and fully equipped operating room to ensure an optimal environment. Carmat has also formed partnerships with other companies and institutions to strengthen its research and development department and share knowledge and experience in the industry. This includes a partnership with Airbus, which supports the company in developing new technologies. Carmat also collaborates with medical facilities to test the artificial hearts and improve their performance. Overall, Carmat is a leading brand in the field of artificial hearts. The company aims to develop innovative products to improve the lives of people with heart failure. It has established itself as a reliable provider of artificial hearts in the market and strives to constantly improve its business activities to meet the growing demand for more effective treatment options for patients with heart problems. Carmat ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Carmat's Shares Outstanding
Carmat's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Carmat’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Carmat’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Carmat’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Carmat stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Carmat are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Carmat evolved in recent years?
The number of shares of Carmat has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Carmat as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Carmat?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Carmat pay?
Over the past 12 months, Carmat paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Carmat is expected to pay a dividend of 0 EUR.
What is the dividend yield of Carmat?
The current dividend yield of Carmat is .
When does Carmat pay dividends?
Carmat pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Carmat?
Carmat paid dividends every year for the past 0 years.
What is the dividend of Carmat?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Carmat located?
Carmat is assigned to the 'Health' sector.
Wann musste ich die Aktien von Carmat kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Carmat from 1/15/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/15/2025.
When did Carmat pay the last dividend?
The last dividend was paid out on 1/15/2025.
What was the dividend of Carmat in the year 2024?
In the year 2024, Carmat distributed 0 EUR as dividends.
In which currency does Carmat pay out the dividend?
The dividends of Carmat are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Carmat
Our stock analysis for Carmat Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Carmat Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
